Prothrombin complex concentrates utility for warfarin-associated hemorrhage.
BACKGROUND
Prothrombin Complex Concentrate (PCC) for reversal of warfarin is the main therapeutic option in cases of life-threatening bleeding. Aim of the study was to investigate for using 4-factor PCC brought to the therapeutic levels of International Normalized Ratio (INR) values in cases of life-threatening bleeding in Emergency Department.


METHODS
This retrospective cohort study was performed in a tertiary care university emergency department. Patients with active bleeding who were taking warfarin with INR levels of ≥1.5, and had received 4-factor prothrombin complex concentrate for treatment were included in to study.


RESULTS
A total of 75 patients were included in the study. The median age of the study participants was 68 (minimum 23 to maximum 87) years and 45.3% (n = 34) of them were male. INR levels was normalized all patients who were received 4-factor PCC. Red blood cell (RBC) was transfused in 16 patients (21%) because of the low hemoglobin levels. Mean unite of the RBC packet was 2,75. The lengths of hospital stay of receiving 4-factor PCC rate were determined 4.9 ± 8.7 days. No thrombotic complications or adverse drug reactions were observed after 4-factor PCC administration in any of the patients.


CONCLUSIONS
In our study 4-factor PCC was found to be effective and safe in rapidly reversing the effects of warfarin.
Department of Emergency Medicine, Akdeniz University School of Medicine Dumlupinar Bulvari, Antalya 07059, Turkey.
Secgin
S
Soyuncu
Department of Emergency Medicine, Akdeniz University School of Medicine Dumlupinar Bulvari, Antalya 07059, Turkey.
Savas
S
Aslan
Department of Emergency Medicine, Akdeniz University School of Medicine Dumlupinar Bulvari, Antalya 07059, Turkey.
Halil
H
Mutlu
Department of Emergency Medicine, Akdeniz University School of Medicine Dumlupinar Bulvari, Antalya 07059, Turkey.
Firat
F
Bektas
Prothrombin complex concentrate; hemorrhage; warfarin